Abstract 124P
Background
BRAF V600E is identified approximately 5-9% of colorectal cancer (CRC) patients. Non-V600E BRAF mutation is characterized a rare molecular subtype. The clinical characteristics and prognostic impact of non-V600 BRAF mutants are not well defined.
Methods
We recruited 829 patients with CRC from our institution. Tissue samples were molecularly tested. Clinical data was retrospectively reviewed and analyzed using Chi-square and t-test. Overall survival (OS) was compared by log-rank test.
Results
All BRAF mutation was detected in 50 (6%) patients including 24 (3%) patients with non-V600 mutations. Patient characteristics and BRAF testing technique were not significantly different based on BRAF status and it was comparable between BRAF V600E and non-V600 groups. There were significantly more ALL RAS and PIK3CA mutations in non-V600 mutant patients. Patients with non-V600 mutation had median OS of 82 months which was longer than BRAF WT, 66 months, and 31 months of BRAF V600E group, respectively (P=0.067). OS according to treatment with anti-EGFR in metastatic CRC patients was not significantly different in both V600E and non-V600 BRAF mutant groups. Table: 124P
BRAF-MT (n=50) | |||||||
BRAF-WT (n=779) | BRAF-MT (n=50) | p-value | V600 (n=26) | non-V600 (n=24) | p-value | ||
Age | 63 (18 - 93) | 65 (19-85) | 66 (19 - 85) | 65 (24 - 83) | |||
Sex | |||||||
Male | 471 (60) | 32 (64) | 0.62 | 15 (58) | 17 (71) | 0.333 | |
Female | 308 (40) | 18 (36) | 11 (42) | 7 (29) | |||
Sidedness | |||||||
Left | 591 (76) | 33 (66) | 0.289 | 12 (70) | 15 (62) | 0.878 | |
Right | 168 (22) | 15 (30) | 7 (27) | 8 (33) | |||
non-specify | 20 (3) | 2 (4) | 1 (4) | 1 (4) | |||
Technique | |||||||
NGS | 547 (70) | 38 (76) | 0.466 | 18 (69) | 20 (83) | 0.26 | |
Pyrosequencing | 84 (11) | 6 (12) | 5 (19) | 1 (4) | |||
PCR | 148 (19) | 6 (12) | 3 (12) | 2 (12) | |||
All RAS mutation | 418 (54) | 8 (16) | <0.001 | 0 | 8 (33) | 0.001 | |
PIK3CA mutation | 94 (12) | 9 (18) | 0.218 | 1 (4) | 8 (33) | 0.009 | |
Recur/Met | (n=575) | (n=35) | (n=19) | (n=16) | |||
Anti-VEGF | 105 (18) | 7 (20) | 0.796 | 2 (11) | 5 (31) | 0.207 | |
Anti-EGFR | 162 (28) | 6 (17) | 0.156 | 3 (16) | 3 (19) | 1 |
Conclusions
Non-V600 BRAF mutation may indicate better prognosis. The difference in treatment effect was not demonstrated in patients with BRAF mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of medicine Ramathibodi Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract